Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: Risk analysis using medicare claims data

Medicine

Volumn 78, Issue 5, 1999, Pages 285-291

  Levitan, Nathan ^a,b   Dowlati, Afshin ^a   Remick, Scot C ^a   Tahsildar, Hassan I ^a   Sivinski, Lynn D ^a   Beyth, Rebecca ^a   Rimm, Alfred A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; HIGH RISK POPULATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICARE; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; RISK MANAGEMENT; THROMBOEMBOLISM;

AGED; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DATABASES; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; LIFE TABLES; MALE; MEDICARE; NEOPLASMS; PATIENT READMISSION; PROBABILITY; PULMONARY EMBOLISM; RECURRENCE; RISK FACTORS; SURVIVAL RATE; UNITED STATES; VENOUS THROMBOSIS;

EID: 0032841392     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-199909000-00001     Document Type: Article

References (44)

1. Aderka D, Brown A, Zelikovski A, Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer 57: 1846-49, 1986.
2. Beyth JB, Cohen AM, Landefeld S. Long term outcomes of deep-vein thrombosis. Arch Intern Med 155: 1031-37, 1995.
3. Clarke-Pearson DL, Synam IS, Creasman WT. Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Am J Obstet Gynecol 147: 369-75, 1983.
4. Coon WW. Anticoagulant therapy. Am J Surg 150(4A): 45-49. 1985.
5. Cooper GS, Yuan Z, Landefeld CS, Rimm AA. Surgery for colorectal cancer Race-related differences in rates and survival among Medicare beneficiaries. Am J Public Health 86: 582-86, 1996.
6. Dore R. Alerci M, D'Andrea F, Di Giulio G, De Agostini A, Volpato G. Intracardiac extension of lung cancer via pulmonary veins: CT diagno-sis. J Comput Assist Tomogr 12: 565-68, 1988.
7. Edwards RL, Rickles FR. Hemostatic alterations in cancer patients. In: Honn KV, Loanie S, eds. Hemostatic mechanism and metastases. Boston: Nishoff, pp 342-54, 1984.
8. Fennerty A, Campbell IA, Routledge PA. Anticoagulants in venous thromboembolism. Br Med J 297: 1285-88, 1988.
9. Fisher BS, Whaley FS, Krushat WM, Malenka DJ, Fleming C, Baron JA, Hsia DC. The accuracy of Medicare's hospital claims data: Progress has been made but problems remain. Am J Public Health 82: 243-48, 1992.
10. Fisher ES, Wennberg JE, Stukel TA, Sharp SM. Hospital readmission rates for cohorts of Medicare beneficiaries in Boston and New Haven. N Engl J Med 331: 989-95, 1994.
11. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota. Mayo Clin Proc 70: 725-33, 1995.
12. Goldberg RJ, Seneff M, Gore JM, Anderson FA, Green HL, Wheeler HB, Dalen JE. Occult malignant neoplasm in patients with deep vein thrombosis. Arch Intern Med 147: 251-53, 1987.
13. Gore JM, Appelbaum JS, Green HL, Dexter L, Dalen JE. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 96: 556-60, 1982.
14. Griffin MR, Stanson AW, Brown ML, Hauser MF, O'Fallon WM, Anderson HM, Kazmeir FJ, Melton LJ. Deep venous thrombosis and pulmonary embolism: Risk of subsequent malignant neoplasms. Arch Intern Med 147: 1907-11, 1987.
15. Holmgren K, Andersson G, Fagrell B, Johnsson H, Ljungberg B, Nillson E, Wilhelmsson S, Zetterqurst S. One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 218: 279-84, 1985.
16. Hsia DC, Krushat M, Fagan AB, Tebbutt JA, Kusserow RP. Accuracy of diagnostic coding for Medicare patients under the prospective-pay-ment system. N Engl J Med 318: 352-55, 1988.
17. Kniffin WD, Baron J, Barret J, Birkmeyer JD, Anderson F. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154: 860-66, 1994.
18. Krauth D, Holden A, Knapic N, Liepman M, Ansell J. Safety and efficacy of long-term oral anticoagulant therapy in cancer patients. Cancer 59: 983-85, 1987.
19. Levine M, Hirsh J. The diagnosis and treatment of thrombosis in the cancer patient. Semin Oncol 17: 160-71, 1990.
20. Liberman JJ, Borrero J, Urdaneta E. Thrombophlebitis and cancer. JAMA 177: 592-95, 1961.
21. McBean AM, Warren JL, Babish JD. Measuring the incidence of cancer in elderly Americans using Medicare claims data. Cancer 73: 2417-25, 1994.
22. Moore FD Jr, Osteen RT, Karp DD, Stein G, Wilson RE. Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg 116: 405-7, 1981.
23. Nordstrom M, Lindbald B, Anderson H, Bergqvist D, Kjellstrom T. Deep venous thrombosis and occult malignancy, an epidemiological study. Br Med J 308; 891-94, 1994.
24. Odero A, Giorgetti P, Cugnasca M, Rampoldi V, Bortolani EM, Ruberti U. Neoplastic thrombosis of the inferior vena cava and right atrium due to kidney cancer. Three surgically treated cases. Panminerva Med 31: 140-43, 1989.
25. O'Sullivan EF. Duration of anticoagulation therapy in venous thromboembolism. Med J Austr 2: 1104-7, 1972.
26. Peterson ED, Jollis JG, Bebchuk JD, DeLong ER, Mulbaiser CM, Mark DB, Pryor DB. Changes in mortality after myocardial revascularization in the elderly. The National Medicare Experience. Ann Intern Med 121: 919-27, 1994.
27. Petitte DB, Strom BL, Melmon KL. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med 81: 255-59, 1986.
28. Prandoni P, Lensing AWA, Buller HR, Cogo A, Prins M, Cattelan AM, Cuppini S, Noverta F, Ten Cate JW. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327: 1128-33, 1992.
29. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Corta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long term clinical course of acute deep venous thrombosis. Ann Intern Med 125: 1-7, 1996.
30. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embosism. Lancet 340: 873-76, 1992.
31. Rickler FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62: 14-31, 1983.
32. Roebuck DJ. Duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 340: 1296, 1992.
33. Sarasin FP, Eckman MH. Management and prevention of thromboembolic events in patients with cancer-related hypercoagulable states: A risky business. J Gen Intern Med 8: 476-86, 1995.
34. Sarasin FP, Bounameaux H. Duration of oral anticoagulant therapy after proximal deep vein thrombosis: A decision analysis. Thromb Haemost 71: 286-91, 1994.
35. Scales SM. Diagnosis and treatment of cancer-related thrombosis. Semin Thromb Hemost 18: 373-79, 1992.
36. Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis: A randomized study. Acta Med Scand 217: 547-52, 1985.
37. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljunberg B, Walter H. A comparison of six weeks with six months of oral anticoagulation therapy after a first episode of venous thromboembolism. N Engl J Med 332: 1661-65, 1995.
38. Soon BC, Miller SP. Coagulation disorders in cancer fibrinolysis and inhibitors. Cancer 25: 867-74, 1970.
39. Sorenson HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338: 1169-73, 1998.
40. Takagi H, Yamada S, Abe T, Ichikawa K, Takezawa J, Nagamine T, Kobayashi S, Katakai S. Hepatocellular carcinoma growing in the pulmonary arteries, complicated with venous thrombosis. Jpn J Med 26: 388-92, 1987.
41. Trousseau A. Phlegmasia alba dolens. Clin Med Hotel Dieu de Paris 3: 94, 1865.
42. Welch WP, Miller ME, Welch HG, Fisher ES, Wennberg JE. Geographic variation in expenditures for physicians' services in the United States. N Engl J Med 328: 621-27, 1993.
43. Wennberg JE, Freeman JL, Shelton RM, Bubolz TA. Hospital use and mortality among Medicare beneficiaries in Boston and New Haven. N Engl J Med 321: 1168-73, 1989.
44. Whittle J, Steinberg EP, Anderson G, Herbert R. Use of Medicare claims data to evaluate outcomes in elderly patients undergoing lung resection for lung cancer. Chest 100: 720-34, 1991.